Helping you navigate long-term care and aging with expert guidance, trusted information, and practical tools.
Explore the full range of long-term care options. From in-home support to assisted living, find straightforward guidance to make informed decisions.
Visit Learning CenterEverything you need to learn about Long-Term Care Insurance in one place. From policy types and benefits to pricing, underwriting, and more.
Visit Learning CenterExplore a range of topics centered around living your best life as you age. Discover practical advice on healthy aging strategies and planning for the future.
All News & TopicsResources and connections for businesses and partners. Access information about LTC News, advertising opportunities, partnerships, and ways to get in touch with our team.
Six-year follow-up data showed that patients receiving zanubrutinib experienced significantly longer progression-free survival than those treated with bendamustine plus rituximab. Researchers also reported strong overall response rates and continued benefit in patients with the high-risk del(17p) genetic abnormality. No new safety concerns were identified during the extended follow-up period.